Markets ▾
Subscribe

BAF NEWS

BAF NEWS

Latest News

Latest

November 2025 US PMI jumps to 54.8 as services surge and data drought lingers

November 2025 US PMI rose to 54.8, its fastest pace since July, signaling continued private-sector expansion despite mixed signals beneath the headline. The article analyzes how November 2025 US PMI reflects diverging trends in services and manufacturing, ongoing data disruptions from the government shutdown, and the outlook for growth and policy.
  • No Comments

Eli Lilly $1 trillion November 2025: What fueled the first pharma to $1 trillion

Eli Lilly $1 trillion November 2025 marks a historic milestone as the company became the first pharmaceutical firm to reach a $1 trillion market value, driven by surging demand for its GLP-1 weight-loss drugs like Mounjaro and Zepbound. The article details the stock's rally, revenue dominance, and competitive landscape, highlighting the significance of this achievement in the pharma sector.
  • No Comments

Nov 20 2025 stock market selloff: Biggest intraday flip since April rattles AI winners

The Nov 20 2025 stock market selloff saw a sharp reversal from morning gains, with volatility spiking and defensives rising as tech and semiconductor stocks slumped. The VIX hit its highest since April, while a delayed jobs report and AI valuation concerns drove risk-off sentiment, impacting global markets.
  • No Comments

November 2025 Bitcoin Falls Below $82K: The Big Flush and What Comes Next

This article analyzes the sharp market downturn as november 2025 bitcoin falls below $82k, detailing the rapid selloff, major liquidations, and the broader impact on crypto markets. It covers the timeline from October’s highs to November’s lows, the role of leverage, and the implications for Bitcoin and altcoins moving forward.
  • No Comments

Treasurer blocks Cosette Mayne Pharma deal as national interest risk trumps takeover

Treasurer blocks Cosette Mayne Pharma deal after accepting FIRB advice that the proposal is not in Australia’s national interest, citing risks to critical medical supply chains and local jobs. The decision triggered a sharp fall in Mayne Pharma shares, a trading halt, and a rescheduled court hearing that will shape future developments.
  • No Comments

Nvidia Q3 2025 earnings: record sales, whipsaw trading, and what’s next

Nvidia Q3 2026 earnings highlighted record revenue of $57.0 billion, with $51.2 billion from data centers, reinforcing Nvidia’s central role in AI infrastructure. The results served as a key indicator for AI spending and market sentiment, while raising questions about customer concentration and chip rental risks.
  • No Comments

AMD Cisco HUMAIN AI joint venture launches with 100 MW Saudi build, 1 GW by 2030

The AMD Cisco HUMAIN AI joint venture is launching with a 100 MW AI data center in Saudi Arabia, aiming to scale up to 1 GW by 2030. The initiative, with AMD and Cisco as minority investors, features Luma AI as its first customer and will use AMD accelerators and Cisco infrastructure for its 2026 debut.
  • No Comments

Japan October 2025 inflation: signals as BOJ December 2025 meeting nears

Japan October 2025 inflation remains above the 2% target, with core at 3.0% and core-core CPI Japan at 3.1%. Firms are actively passing on higher costs, and the Japan PMI November 2025 shows faster input-cost growth. These trends will shape the BOJ's policy decisions at the December 2025 meeting.
  • No Comments

GE HealthCare Intelerad $2.3 billion acquisition: Cloud-first imaging’s next big bet

The GE HealthCare Intelerad $2.3 billion acquisition, announced in November 2025, marks a strategic move to unify imaging data through cloud-enabled, AI-driven software across outpatient and hospital settings. The deal aims for workflow efficiency, strong recurring revenue, and positions GE HealthCare for growth in the enterprise imaging market.
  • No Comments

November 2025 healthcare news roundup: deals, approvals, and policy shifts

This November 2025 healthcare news roundup covers major industry developments, including GE HealthCare’s $2.3B Intelerad acquisition, FDA approval of Arrowhead’s REDEMPLO for FCS, CMS’s 2026 ESRD payment rule, a new FDA clarification pilot, and Senate progress on the HHS inspector general nominee.
  • No Comments

Trending

Dick’s Sporting Goods raises 2025 guidance after Q3 results
Dick's Sporting Goods raises 2025 guidance after reporting strong Q3 results, increasing its comparable sales growth outlook to 3.5%–4.0% and adjusted EPS to $14.25–$14.55. The update reflects resilient demand and broad-based momentum, though shares fell as investors weighed execution risks.
Wegovy 7.2 mg FDA filing: Faster review, bigger weight loss, and the next deadlines
The Wegovy 7.2 mg FDA filing marks Novo Nordisk's bid to introduce a higher once-weekly dose for adults with obesity, aiming for faster review under the FDA's accelerated pilot program. The application builds on STEP UP trial data, showing greater average weight loss, and could lead to a decision within 1–2 months if accepted.
RBNZ cuts OCR to 2.25% as easing cycle extends into 2026
RBNZ cuts OCR to 2.25% as the central bank extends its easing cycle to support New Zealand’s fragile recovery. The decision, made by a 5–1 monetary policy committee vote, reflects ongoing disinflation and a cautious, data-dependent approach, with inflation projected to reach 2% by mid-2026.

Stay in the loop